Be the first person to write a business review for AutoImmune Inc.

Avacta will take a closer look and get back with you. The biophysics company makes its money from the exact science of detecting molecules. Its Avacta Analysis arm provides analytical and research services to the pharmaceutical, healthcare, and personal care industries. It also offers expert witness services to assist in pharmaceutical patent disputes and suspected counterfeiting cases. The company's technology arm has developed a product to help drug developers analyze and predict the potential usefulness of biological drug compounds. The company also owns veterinary laboratory services provider YorkTest Veterinary Services, and diagnostic test maker Curidium Medica.

Avalon Pharmaceuticals doesn't mind if genes express themselves -- but they should know that anything they express can and will be used against them if they lead to cancer. The biopharmaceutical firm develops cancer therapeutics based on its AvalonRx platform, which identifies compounds that would be best suited to advance in clinical drug development. Lead product AVN944, an inhibitor of hematologic (leukemia, lymphoma, and myeloma) and solid tumor cancers, is an oral drug now in clinical trials. Avalon also has preclinical programs to develop inhibitors through partnerships with other drug companies. The company was acquired by Clinical Data in 2009.

AVAX Technologies company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate M-Vax is intended as a post-surgical treatment for late-stage melanoma, but the company is also developing vaccine candidates to fight ovarian cancer (O-Vax) and non-small cell lung cancer (L-Vax). The company also offers contract manufacturing services to other biotech and pharmaceutical companies.

AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.